Dublin, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2010 to 2021" report has been added to ResearchAndMarkets.com's offering.
The Global Gene Therapy Partnering Agreements 2010-2021 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 650 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
In addition, a comprehensive appendix is provided organized by Gene Therapy partnering company A-Z, deal type definitions and Gene Therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report Scope
Global Gene Therapy Partnering Terms and Agreements includes:
- Trends in gene therapy dealmaking in the biopharma industry since 2010
- Access to headline, upfront, milestone and royalty data
- Access to over 650 gene therapy deals
- The leading gene therapy deals by value since 2010
- Most active gene therapy dealmakers since 2010
- The leading gene therapy partnering resources
In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Gene therapy dealmaking
2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Most active Gene therapy dealmakers
2.4. Gene therapy partnering by deal type
2.5. Gene therapy partnering by therapy area
2.6. Deal terms for Gene therapy partnering
2.6.1 Gene therapy partnering headline values
2.6.2 Gene therapy deal upfront payments
2.6.3 Gene therapy deal milestone payments
2.6.4 Gene therapy royalty rates
Chapter 3 - Leading Gene therapy deals
3.1. Introduction
3.2. Top Gene therapy deals by value
Chapter 4 - Most active Gene therapy dealmakers
4.1. Introduction
4.2. Most active Gene therapy dealmakers
4.3. Most active Gene therapy partnering company profiles
Chapter 5 - Gene therapy contracts dealmaking directory
5.1. Introduction
5.2. Gene therapy contracts dealmaking directory
Chapter 6 - Gene therapy dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Gene therapy deals by company A-Z
Appendix 2 - Gene therapy deals by stage of development
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Regulatory
- Marketed
- Formulation
Appendix 3 - Gene therapy deals by deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Research
- Spin out
- Sub-license
- Supply
- Technology transfer
Appendix 4 - Gene therapy deals by therapy area
- Cardiovascular
- Central Nervous System
- Genetic disorders
- Hematology
- Immunology
- Infectives
- Metabolic
- Musculoskeletal
- Obstetrics
- Oncology
- Ophthalmics
- Orphan disease
- Pediatrics
- Respiratory
Appendix 5 -Deal type definitions
Companies Mentioned
- National Cancer Institute
- deCODE Genetics
- Merck and Co
- IGEA Clinical Biophysics
- Monsanto
- BIA Separations
- University of Pennsylvania School of Veterinary Medicine
- University of Florida Research Foundation
- Avacta
- Santhera Pharmaceuticals
- Rocket Pharmaceuticals
- University of Iowa
- Galapagos
- University of Massachusetts
- Lund University
- Aruvant Sciences
- Allen Institute for Brain Science
- Scenic Biotech
- Duke Clinical Research Institute (DCRI)
- Cangene
- GeoVax
- ALS Therapy Development Institute
- Lawrence Berkeley National Laboratory
- Sitoa
- Ambys Medicines
- National Institute of Standards and Technology
- Quark Pharmaceuticals
- UniQure
- Renovo
- Catalent
- Concord Medical Services Holdings
- Japan Tobacco
- New Jersey Innovation Institute
- ARCA Biopharma
- The Parker Institute For Cancer Immunotherapy
- Ipsen
- Yale University
- Expression Therapeutics
- Alnylam Pharmaceuticals
- University of Pittsburgh Medical Center
- Janssen Pharmaceuticals
- Fujifilm Diosynth Biotechnologies
- Gene Therapy Research Institution
- MilliporeSigma
- GlaxoSmithKline
- Foundation Fighting Blindness
- Kangmei Pharma
- AffyXell Therapeutics
- Boehringer Ingelheim
- National Institute of Neurological Disorders and Stroke
For more information about this report visit https://www.researchandmarkets.com/r/ttwumz
